- Home
- ETW vs SNDX Comparison
ETW vs SNDX Comparison
Compare ETW & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETW
- SNDX
- Stock Information
- Founded
- ETW 2005
- SNDX 2005
- Country
- ETW United States
- SNDX United States
- Employees
- ETW N/A
- SNDX N/A
- Industry
- ETW Investment Managers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ETW Finance
- SNDX Health Care
- Exchange
- ETW Nasdaq
- SNDX Nasdaq
- Market Cap
- ETW 966.5M
- SNDX 1.1B
- IPO Year
- ETW N/A
- SNDX 2016
- Fundamental
- Price
- ETW $9.00
- SNDX $16.33
- Analyst Decision
- ETW
- SNDX Strong Buy
- Analyst Count
- ETW 0
- SNDX 10
- Target Price
- ETW N/A
- SNDX $37.50
- AVG Volume (30 Days)
- ETW 284.6K
- SNDX 3.0M
- Earning Date
- ETW 01-01-0001
- SNDX 08-04-2025
- Dividend Yield
- ETW 8.61%
- SNDX N/A
- EPS Growth
- ETW N/A
- SNDX N/A
- EPS
- ETW N/A
- SNDX N/A
- Revenue
- ETW N/A
- SNDX $77,933,000.00
- Revenue This Year
- ETW N/A
- SNDX $585.73
- Revenue Next Year
- ETW N/A
- SNDX $94.17
- P/E Ratio
- ETW N/A
- SNDX N/A
- Revenue Growth
- ETW N/A
- SNDX 2126.66
- 52 Week Low
- ETW $6.96
- SNDX $8.58
- 52 Week High
- ETW $8.49
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- ETW 64.78
- SNDX 75.36
- Support Level
- ETW $8.86
- SNDX $15.29
- Resistance Level
- ETW $8.93
- SNDX $17.24
- Average True Range (ATR)
- ETW 0.07
- SNDX 0.79
- MACD
- ETW 0.00
- SNDX 0.05
- Stochastic Oscillator
- ETW 92.00
- SNDX 80.30
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.